JP2021527049A5 - - Google Patents
Info
- Publication number
- JP2021527049A5 JP2021527049A5 JP2020567815A JP2020567815A JP2021527049A5 JP 2021527049 A5 JP2021527049 A5 JP 2021527049A5 JP 2020567815 A JP2020567815 A JP 2020567815A JP 2020567815 A JP2020567815 A JP 2020567815A JP 2021527049 A5 JP2021527049 A5 JP 2021527049A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition according
- mitochondrial
- deficiency
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382397 | 2018-06-06 | ||
| EP18382397.0 | 2018-06-06 | ||
| PCT/IB2019/054696 WO2019234664A1 (en) | 2018-06-06 | 2019-06-06 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527049A JP2021527049A (ja) | 2021-10-11 |
| JP2021527049A5 true JP2021527049A5 (enExample) | 2022-06-14 |
| JP7376934B2 JP7376934B2 (ja) | 2023-11-09 |
Family
ID=62716008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567815A Active JP7376934B2 (ja) | 2018-06-06 | 2019-06-06 | ミトコンドリア性疾患の処置における使用のための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンおよびその塩 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11957670B2 (enExample) |
| EP (2) | EP3801515B1 (enExample) |
| JP (1) | JP7376934B2 (enExample) |
| DK (1) | DK3801515T3 (enExample) |
| ES (1) | ES3028538T3 (enExample) |
| FI (1) | FI3801515T3 (enExample) |
| HR (1) | HRP20250591T1 (enExample) |
| HU (1) | HUE071482T2 (enExample) |
| LT (1) | LT3801515T (enExample) |
| PL (1) | PL3801515T3 (enExample) |
| PT (1) | PT3801515T (enExample) |
| SI (1) | SI3801515T1 (enExample) |
| WO (1) | WO2019234664A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| MX2020013181A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| CA3127590A1 (en) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
| EP3917509A4 (en) | 2019-01-28 | 2022-11-09 | Mitochondria Emotion, Inc. | TRANS-4-HYDROXYCYCLOHEXYLPHENYLAMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362165A (zh) | 2011-01-10 | 2017-11-21 | 金帆德尔制药股份有限公司 | 用于治疗阿尔茨海默病的方法和药物产品 |
| EP3013371A4 (en) | 2013-06-26 | 2017-04-26 | Rett Syndrome Research Trust | Rett syndrome and treatments therefore |
| ES2831326T3 (es) | 2014-01-15 | 2021-06-08 | Poxel Sa | Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio |
| NZ725492A (en) | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| US20180364595A1 (en) | 2015-09-30 | 2018-12-20 | Nikon Corporation | Exposure apparatus, flat panel display manufacturing method, and device manufacturing method |
| WO2017083739A1 (en) | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| CN106202285A (zh) | 2016-06-30 | 2016-12-07 | 北京百度网讯科技有限公司 | 搜索结果展示方法和装置 |
| MX379710B (es) | 2016-12-01 | 2025-03-11 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. |
| CN110198945B (zh) | 2016-12-23 | 2023-06-27 | 米尼奥尔克斯治疗有限公司 | 用于制备噻唑烷二酮化合物及其盐的方法 |
| MX2020013181A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| MX2020013182A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. |
-
2019
- 2019-06-06 HU HUE19742480A patent/HUE071482T2/hu unknown
- 2019-06-06 US US16/972,375 patent/US11957670B2/en active Active
- 2019-06-06 FI FIEP19742480.7T patent/FI3801515T3/fi active
- 2019-06-06 SI SI201930937T patent/SI3801515T1/sl unknown
- 2019-06-06 WO PCT/IB2019/054696 patent/WO2019234664A1/en not_active Ceased
- 2019-06-06 DK DK19742480.7T patent/DK3801515T3/da active
- 2019-06-06 PL PL19742480.7T patent/PL3801515T3/pl unknown
- 2019-06-06 HR HRP20250591TT patent/HRP20250591T1/hr unknown
- 2019-06-06 EP EP19742480.7A patent/EP3801515B1/en active Active
- 2019-06-06 PT PT197424807T patent/PT3801515T/pt unknown
- 2019-06-06 EP EP25162244.5A patent/EP4545142A3/en active Pending
- 2019-06-06 LT LTEPPCT/IB2019/054696T patent/LT3801515T/lt unknown
- 2019-06-06 ES ES19742480T patent/ES3028538T3/es active Active
- 2019-06-06 JP JP2020567815A patent/JP7376934B2/ja active Active
-
2024
- 2024-04-12 US US18/633,922 patent/US20250064791A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527061A5 (enExample) | ||
| EP3600318A1 (en) | Methods of using ehmt2 inhibitors | |
| BR102018004952A2 (pt) | composição farmacêutica, e, método para tratar uma doença ou distúrbio mediado por jak | |
| EP4309738A2 (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
| AU2009321722B2 (en) | Methods for preventing or reducing colon carcinogenesis | |
| EP2089023A2 (en) | Methods of treating neuropathic pain with agonists of ppar-gamma | |
| US20100069433A1 (en) | Prophylactic and/or therapeutic agent for hyperlipidemia | |
| MX2013005561A (es) | Metodo para tratar enfermedades de los ojos asociadas con inflamacion o proliferacion vascular. | |
| JP7510170B2 (ja) | ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用 | |
| JP2021527045A5 (enExample) | ||
| US20250064791A1 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases | |
| JP2025504963A5 (enExample) | ||
| US7846968B2 (en) | Methods for QT interval control | |
| US6632838B1 (en) | Use of bissulfonamides for producing medicines for the treatment of hyperlipidemia | |
| DK2882708T3 (en) | NEW CONNECTIONS AND APPLICATIONS THEREOF | |
| US20150210679A1 (en) | Small molecule inhibitors of superoxide dismutase expression | |
| BG63367B1 (bg) | Нитробензамиди, полезни като противоаритмични средства | |
| EP3911319A1 (en) | Substituted fused imidazole derivatives and methods of treating sickle cell disease and related complications | |
| CN101507726B (zh) | 窦房结If电流抑制剂和β-阻滞剂的组合 | |
| EP3377476B1 (en) | Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof | |
| US12343316B2 (en) | Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases | |
| JP2014506565A5 (enExample) | ||
| KR20240004620A (ko) | 미타피바트를 적정하는 방법 | |
| JP2022515156A5 (enExample) | ||
| CN102731400A (zh) | 一种盐酸伊伐布雷定的新晶型、制备方法及其在制备药物组合物中的用途 |